Comparative genomic analysis of primary versus metastatic colorectal carcinomas

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages 2956-2962

  Vakiani, Efsevia ^a   Janakiraman, Manickam ^a   Shen, Ronglai ^a   Sinha, Rileen ^a   Zeng, Zhaoshi ^a   Shia, Jinru ^a   Cercek, Andrea ^a   Kemeny, Nancy ^a   D'Angelica, Michael ^a   Viale, Agnes ^a   Heguy, Adriana ^a   Paty, Philip ^a   Chan, Timothy A ^a   Saltz, Leonard B ^a   Weiser, Martin ^a   Solit, David B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53;

ARTICLE; BRAF GENE; CANCER TISSUE; COLORECTAL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE; GENE DOSAGE; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KRAS GENE; MAJOR CLINICAL STUDY; METASTASIS; MUTATIONAL ANALYSIS; NRAS GENE; ONCOGENE K RAS; ONCOGENE N RAS; PIK3CA GENE; PRIMARY TUMOR; PRIORITY JOURNAL; TP53 GENE;

COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; MALE; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84865186133     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2994     Document Type: Article

References (39)

1. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
2. Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379, 2008
3. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007
4. Freeman DJ, Juan T, Reiner M, et al: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184-190, 2008
5. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
6. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
7. Loupakis F, Ruzzo A, Cremolini C, et al: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715-721, 2009
8. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
9. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851-1857, 2009
10. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
11. Tol J, Dijkstra JR, Vink-Börger ME, et al: High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 14:2122-2131, 2010
12. Prenen H, De Schutter J, Jacobs B, et al: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15:3184-3188, 2009
13. Perrone F, Lampis A, Orsenigo M, et al: PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84-90, 2009
14. Oden-Gangloff A, Di Fiore F, Bibeau F, et al: TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximabbased chemotherapy. Br J Cancer 100:1330-1335, 2009
15. Kim JS, Lee C, Bonifant CL, et al: Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol 27:662-677, 2007
16. Janakiraman M, Vakiani E, Zeng Z, et al: Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 70: 5901-5911, 2010
17. Pratilas CA, Hanrahan AJ, Halilovic E, et al: Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375-9383, 2008
18. Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
19. Venkatraman ES, Olshen AB: A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23:657-663, 2007
20. McCarroll SA, Kuruvilla FG, Korn JM, et al: Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 40:1166-1174, 2008
21. Knijn N, Mekenkamp LJ, Klomp M, et al: KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104: 1020-1026, 2011
22. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2010
23. Ostrovnaya I, Olshen AB, Seshan VE, et al: A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Stat Med 29:1608-1621, 2010
24. Ostrovnaya I, Seshan VE, Olshen AB, et al: Clonality: An R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 27:1698-1699, 2011
25. Girard N, Ostrovnaya I, Lau C, et al: Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 15:5184-5190, 2009
26. Bollet MA, Servant N, Neuvial P, et al: High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst 100:48-58, 2008
27. Etienne-Grimaldi MC, Formento JL, Francoual M, et al: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14:4830- 4835, 2008
28. Santini D, Loupakis F, Vincenzi B, et al: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 13:1270-1275, 2008
29. Italiano A, Hostein I, Soubeyran I, et al: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications. Ann Surg Oncol 17:1429-1434, 2010
30. Oliveira C, Velho S, Moutinho C, et al: KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26:158-163, 2007
31. Albanese I, Scibetta AG, Migliavacca M, et al: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 325:784-791, 2004
32. Bossard C, Jamet P, Bezieau S, et al: Does testing of KRAS in patients with metastatic colorectal cancer offer valuable information in deciding treatment options? Mod Pathol 23:138A, 2010 (abstr)
33. Houlle S, Lamy A, Blanchard F, et al: Metastatic CRCs KRAS and BRAF genotyping in routine diagnosis: Results and pitfalls. Mod Pathol 23:148A, 2010 (abstr)
34. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
35. Chu DZ, Giacco G, Martin RG, et al: The significance of synchronous carcinoma and polyps in the colon and rectum. Cancer 57:445-450, 1986
36. Finan PJ, Ritchie JK, Hawley PR: Synchronous and 'early' metachronous carcinomas of the colon and rectum. Br J Surg 74:945-947, 1987
37. Lasser A: Synchronous primary adenocarcinomas of the colon and rectum. Dis Colon Rectum 21:20-22, 1978
38. Ogino S, Brahmandam M, Kawasaki T, et al: Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 19:1083-1090, 2006
39. Solassol J, Ramos J, Crapez E, et al: KRAS mutation detection in paired frozen and formal-infixed paraffin-embedded (FFPE) colorectal cancer tissues. Int J Mol Sci 12:3191-3204, 2011